Loading stock data…
$79.31-0.31 (-0.39%)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Mirum Pharmaceuticals, Inc. in the Healthcare sector is trading at $78.89 with a market capitalization of $6.0B. Wall Street consensus targets $151.64 (14 analysts), implying a +92.2% move over the next 12 months. The stock is currently 39% below its 52-week high of $130.00, remaining 19.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $176.24M↑ | $159.88M↑ | $148.93M↑ | $133.01M↑ | $127.78M |
| Gross Profit | $145.90M↑ | $131.08M↑ | $120.67M↑ | $107.47M↑ | $104.36M |
| Operating Income | -$26.10M↑ | -$63.16M↓ | -$4.57M↓ | $2.60M↑ | -$4.99M |
| Net Income | -$67.23M↑ | -$790.15M↓ | -$5.73M↓ | $2.90M↑ | -$5.86M |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and ...